Recent Company News

• 09:59 PM ET May 27, 2025
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 12:52 AM ET Jun 23, 2025
  

  StreetAccount Summary: Australia and New Zealand Stocks reaching new 52-week highs/lows (40 total)

• 12:54 AM ET Jun 13, 2025
  

  StreetAccount Summary: Australia and New Zealand Stocks reaching new 52-week highs/lows (42 total)

• 07:48 PM ET Jun 17, 2025
  

  Clinuvel Pharmaceuticals Phase II study of SCENESSE as monotherapy fails to demonstrate repigmentation in skin of three adult vitiligo patients (A$9.76, 0.00)

• 01:03 AM ET Jun 16, 2025
  

  StreetAccount Summary: Australia and New Zealand Stocks reaching new 52-week highs/lows (58 total)

• 07:41 PM ET Jun 12, 2025
  

  Clinuvel Pharmaceuticals notes return of Philippe Wolgen in the role of Managing Director (A$10.18, 0.00)

• 07:04 PM ET Jun 12, 2025
  

  SCENESSE successfully administered to paediatric EPP patient (A$10.18, 0.00)